Dr. Gervasio Lamas is the Principal Investigator and Chair of the Trials to Access Chelation Therapy (TACT). After the initial 10-year TACT study, Dr. Lamas found extraordinary results, particularly relating to diabetic patients.
With such promising results, he was then asked to continue his studies through TACT 2, which is currently collecting data, and the upcoming TACT 3A. This fascinating update shows an exciting look at the future of Chelation Therapy!
The American College for Advancement in Medicine (ACAM) is a not-for-profit organization dedicated to educating physicians and other health care professionals on the safe and effective application of integrative medicine.